Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
- Published in:
- OncoImmunology, 2021, v. 10, n. 1, p. 1, doi. 10.1080/2162402X.2021.1899469
- By:
- Publication type:
- Article